| Bid | 0.7 |
| Market Cap | 80.24M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.13 |
| PE Ratio (ttm) | -5.58 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 0.76 |
| Volume | 131,954 |
| Avg. Volume (20D) | 373,360 |
| Open | 0.75 |
| Previous Close | 0.75 |
| Day's Range | 0.72 - 0.76 |
| 52-Week Range | 0.41 - 1.74 |
| Beta | undefined |
About TLSA
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. I...
5 days ago · proactiveinvestors.com
Tiziana Life Sciences' foralumab reduces side effects of discontinuing GLP-1 agonistsTiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its intranasal anti-CD3 monoclonal antibody, foralumab, has demonstrated the ability to mitigate the side effects associated with the discontinua...
1 week ago · proactiveinvestors.com
Tiziana Life Sciences welcomes publication of article highlighting foralumab's potential in neurological diseasesTiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the publication of a review article in Nature Reviews Neurology that examines the potential of its lead therapeutic candidate intranasal foralumab...
4 weeks ago · proactiveinvestors.com
Tiziana Life Sciences doses first Alzheimer's patient with intranasal foralumabTiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has dosed the first patient with moderate Alzheimer's disease with its lead investigational drug candidate intranasal foralumab. The company s...
1 month ago · proactiveinvestors.com
Tiziana Life Sciences expands Phase 2 MS trial to additional top US medical institutionsTiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has expanded its Phase 2 clinical trial evaluating intranasal foralumab for non-active secondary progressive multiple sclerosis (SPMS) to addi...
2 months ago · proactiveinvestors.com
Tiziana Life Sciences CEO discusses foralumab potential to enhance Ozempic - ICYMITiziana Life Sciences Ltd (NASDAQ:TLSA) this week announced positive research findings showing the anti-inflammatory potential of the company's nasal anti-CD3 antibody foralumab when used in combinati...
2 months ago · proactiveinvestors.com
Tiziana Life Sciences to showcase breakthrough therapies at BIO-Europe 2024 ConferenceTiziana Life Sciences Ltd (NASDAQ:TLSA) said it will participate in the upcoming BIO-Europe 2024 conference in Stockholm. The event will allow Tiziana to engage with industry leaders, potential collab...
2 months ago · proactiveinvestors.com
Tiziana Life Sciences secures funding to advance development of MS and Alzheimer's therapyTiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has secured up to $10 million in funding through a registered direct offering. The offering includes an initial investment of approximately $5...
2 months ago · proactiveinvestors.com
Tiziana Life Sciences reports promising preclinical results for novel combination therapy targeting obesityTiziana Life Sciences Ltd (NASDAQ:TLSA) has reported positive results from a preclinical study evaluating the combination of its lead development candidate intranasal foralumab and semaglutide, which ...